Filippo Lodi
Overview
Explore the profile of Filippo Lodi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
648
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brusa I, Cabitza V, Emiliani S, Malizia C, Fortunati E, Zanoni L, et al.
Nucl Med Biol
. 2025 Feb;
140-141:108974.
PMID: 39999572
Background: Due to the increasing application of the fibroblast activation protein (FAP) targeting radiotracer [Ga]Ga-FAPI-46 in cancer diagnostics by PET/CT, there is a need for a convenient way for routine...
2.
Zanoni L, Fortunati E, Cuzzani G, Malizia C, Lodi F, Cabitza V, et al.
Pharmaceuticals (Basel)
. 2024 Nov;
17(11).
PMID: 39598380
Background/objectives: To evaluate T&N-staging diagnostic performance of [68Ga]Ga-FAPI-46 PET/CT (FAPI) in a suspected/confirmed lung cancer surgical cohort. Methods: Patients were enrolled in a prospective monocentric trial (EudraCT: 2021-006570-23) to perform...
3.
Bernardes E, Caravan P, van Dam R, Deuther-Conrad W, Ellis B, Furumoto S, et al.
EJNMMI Radiopharm Chem
. 2022 Apr;
7(1):9.
PMID: 35471681
Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Results: This commentary of...
4.
Zanoni L, Bianchi L, Nanni C, Pultrone C, Giunchi F, Bossert I, et al.
Eur J Nucl Med Mol Imaging
. 2021 Jul;
49(1):390-409.
PMID: 34213609
Purpose: The conventional imaging flowchart for prostate cancer (PCa) staging may fail in correctly detecting lymph node metastases (LNM). Pelvic lymph node dissection (PLND) represents the only reliable method, although...
5.
Zanoni L, Mei R, Bianchi L, Giunchi F, Maltoni L, Pultrone C, et al.
Cancers (Basel)
. 2021 Apr;
13(7).
PMID: 33805543
The primary aim of the study was to evaluate the role of [F]Fluciclovine PET/CT in the characterization of intra-prostatic lesions in high-risk primary PCa patients eligible for radical prostatectomy, in...
6.
Calderoni L, Farolfi A, Pianori D, Maietti E, Cabitza V, Lambertini A, et al.
J Nucl Med
. 2019 Oct;
61(5):716-722.
PMID: 31601704
Ga-labeled urea-based inhibitors of the prostate-specific membrane antigen (PSMA), such as Ga-PSMA-11, are promising small molecules for targeting prostate cancer (PCa). Although this radiopharmaceutical was produced mostly by means of...
7.
Zanoni L, Broccoli A, Lambertini A, Pellegrini C, Stefoni V, Lodi F, et al.
Eur J Nucl Med Mol Imaging
. 2019 May;
46(8):1661-1671.
PMID: 31102000
Purpose: To evaluate the role of F-18-Fluorothymidine (FLT) PET/CT in lymphoma patients with suspected recurrent or residual disease. Methods: Adult lymphoma patients presenting with positive or equivocal F-18-FDG PET/CT at...
8.
Calderoni L, Matei Deliu V, Farolfi A, Lambertini A, Renne G, Lorenzini D, et al.
Clin Genitourin Cancer
. 2018 Dec;
17(2):e356-e359.
PMID: 30558835
No abstract available.
9.
Riga S, Cicoria G, Pancaldi D, Zagni F, Vichi S, Dassenno M, et al.
Phys Med
. 2018 Nov;
55:116-126.
PMID: 30473059
Purpose: In recent years the use of Ga (t = 67.84 min, β: 88.88%) for the labelling of different PET radiopharmaceuticals has significantly increased. This work aims to evaluate the...
10.
Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, et al.
Eur J Nucl Med Mol Imaging
. 2018 Oct;
46(1):31-39.
PMID: 30350010
Objectives: The primary objective was the evaluation of Gallium 68 (Ga)-prostate-specific membrane antigen (PSMA)-11 positron emission tomography/computed tomography (PET/CT) detection rate, for identifying the site of prostate cancer (PCa) relapse...